LINKER-MM1
LINKER-MM1 is the pivotal study for linvoseltamab, with 45% complete responses.
ORR 70%, ≥CR 45%; median PFS not reached at 14 months. Basis for July 2025 accelerated approval.
- 70 out of 100 people had their tumour shrink with Linvoseltamab 200 mg.
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Relapsed/refractory myeloma after ≥3 lines: linvoseltamab 200 mg. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
117 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rateprimary | Linvoseltamab 200 mg | 117 | 70% | — | — | — |
Pages like this
not linked directly; found by shared links- PairingCaution: T-cell redirectors and infections
Shares Linvoseltamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TrialMagnetisMM-3
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TargetGPRC5D
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- ProductTalquetamab
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- ProductElranatamab
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- CompanyRegeneron
Shares Linvoseltamab, Multiple myeloma.
- Key paperMajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.
- TargetBCMA
Shares Linvoseltamab, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Multiple myeloma.